Although weight loss, diet, and exercise play a major role, certain therapies including GLP-1 receptor agonists, resmetirom, lanifibranor, and FGF-3 analogs are showing promise when treating patients with MASLD. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.